There are currently 437 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University of Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
NCT04150497
Recruiting
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Gender:
ALL
Ages:
Between 15 years and 50 years
Trial Updated:
06/12/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT04172532
Recruiting
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738
Recruiting
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Research Site, Buffalo, New York
Conditions: Non-small Cell Lung Cancer
Register for Updates
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain
NCT04333576
Recruiting
Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endomet... Read More
Gender:
FEMALE
Ages:
Between 18 years and 49 years
Trial Updated:
06/12/2025
Locations: Invision Health /ID# 218687, Buffalo, New York
Conditions: Endometriosis
Register for Updates
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917
Recruiting
This study is a prospective, multicenter, randomized controlled trial of an interventional strategy using the ClotTriever System to achieve and maintain vessel patency (ClotTriever Intervention Arm) versus conservative medical management using anticoagulation therapy alone (Conservative Medical Management Arm) in the treatment of subjects with symptomatic unilateral iliofemoral DVT. The study will collect data on demographics, comorbidities, details from the DVT diagnosis and treatment, and clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: SUNY, The University at Buffalo, Buffalo, New York
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Register for Updates
A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
NCT06833255
Recruiting
This clinical trial studies whether a post-treatment supportive service program can be used to help Black women breast cancer survivors in Western New York (WNY) transition into post-treatment life (survivorship). Programming for Black cancer survivors in WNY is crucially needed. Poverty and cancer have affected the region for years. The post-treatment supportive service program is delivered to Black women breast cancer survivors of WNY. It combines group support sessions and one-on-one (1:1) pe... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Breast Carcinoma
Register for Updates
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
NCT05826743
Recruiting
The purpose of this study is to evaluate the Colorectal Balloon Tube (hereinafter referred to as COLO-BT™) device, a single use, temporary intraluminal bypass device, intended to reduce contact of fecal content with an anastomotic site, following colorectal surgery (open or laparoscopic)
Gender:
ALL
Ages:
Between 19 years and 80 years
Trial Updated:
06/12/2025
Locations: Jacobs School of Medicine & Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York
Conditions: Colorectal Surgery, Colorectal Cancer, Rectal/Anal, Ileostomy - Stoma, Anastomotic Leakage
Register for Updates
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05061550
Recruiting
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 95 years
Trial Updated:
06/11/2025
Locations: Research Site, Buffalo, New York
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-nul... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/11/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Advanced MTAP-null Solid Tumors
Register for Updates
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
NCT06456463
Recruiting
This study will be divided into 2 parts (Part 1 and Part 2). Part 1 will evaluate 2 doses of tagraxofusp (9 and 12 micrograms/kilogram/day \[μg/kg/day\]), used in combination with venetoclax and azacitidine, to determine the dose for Part 2. This determined dose, in combination with venetoclax and azacitidine, will then be further evaluated in Part 2 in 2 cohorts (TP53 mutated and TP53 wild type). Both parts will be conducted in participants with previously untreated CD123+ AML who are ineligibl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Acute Myeloid Leukemia
Register for Updates
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT05809752
Recruiting
The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer
Register for Updates
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/10/2025
Locations: Great Lakes Cancer Center, Buffalo, New York
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Register for Updates